

Reg. Office: Office No. 201, Citi Mall, Link Road, Andheri West, Mumbai - 400053 Email ID: rubraltd@gmail.com | Website: www.rubramed.com CIN: L74110MH1991PLC326598 | Tel: +91 9167469649

November 18, 2019

To, BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400 001

Scrip Code : <u>531099</u>

Sub : Outcome of Board Meeting

Dear Sir / Madam,

With respect to our outcome uploaded on November 14, 2019 regarding Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2019 and Limited Review Report thereon, we had inadvertently not uploaded Cash Flow Statement for the half year ended September 30, 2019 in the note thereto. The same is attached herewith.

We request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For Rubra Medicaments Limited

Abha Kapoor

Director (Finance) and CFO

DIN - 02799429

RUBRA MEDICAMENTS LIMITED

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2019

A Cash Flow From Operating Activities Net Profit before tax and Extraordinary Items Adjustment for: Depreciation 9,249 3,630 Operating Profit before working Capital Changes (183,946) (1,820,952) Adjustment for Capital Changes: Increase/Decrease in Payables & Provisions 68,240 26,605 Cash Generated From Operations (283,777) (1,962,418) Income Tax / Deferred Tax Paid - (1,710,556) Net cash from Operating Activities (283,777) (251,862) B Net Cash From Investing Activities (168,071) Increase/Decrease in Capital WIP (1,401,358) - Net Cash From Investing Activities (1,569,429) (168,071) Net Cash From Investing Activities (1,569,429) (168,071)		Particulars	30-Sep-19	31-Mar-19
Adjustment for: Depreciation 9,249 3,630 Operating Profit before working Capital Changes (183,946) (1,820,952) Adjustment for Capital Changes: Increase/Decrease in Payables & Provisions 68,240 26,605 Cash Generated From Operations Income Tax / Deferred Tax Paid Extraordinary items (1,710,556) Net cash from Operating Activities (283,777) (251,862) B Net Cash From Investing Activities (283,777) (251,862) B Net Cash From Investing Activities (168,071) (168,07	<u>A</u>	Cash Flow From Operating Activities	RUPEES	RUPEES
Operating Profit before working Capital Changes Increase/Decrease in Payables & Provisions Cash Generated From Operations Income Tax / Deferred Tax Paid Extraordinary items Net cash from Operating Activities Increase/Decrease in Capital WIP Net Cash From Investing Activities Cash Flow From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase (Decrease) in cash & cash equivalents Net Cash From Financing Activities Increase (Decrease) in cash & cash equivalents Net Cash From Financing Activities Increase (Decrease) in cash & cash equivalents Increase (Decrease) in cash & cash equivalents Net Increase (Decrease) in cash & cash equivalents Increase (Decrease) Incash & Cash Equivalents Increase (D		•	(193,195)	(1,824,582)
Adjustment for Capital Changes: Increase/Decrease in Payables & Provisions Cash Generated From Operations Income Tax / Deferred Tax Paid Extraordinary items Net cash from Operating Activities Net cash from Operating Activities Increase/Decrease in Fixed Assets Increase/Decrease in Capital WIP Net Cash From Investing Activities Net Cash From Investing Activities Net Cash From Investing Activities Net Cash From Investing Activities Increase/Decrease in Trade Payables Increase/Decrease in Trade Payables Increase/Decrease in Trade Payables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables		Depreciation	9,249	3,630
Increase/Decrease in Payables & Provisions 68,240 26,605 Cash Generated From Operations (1,962,418) Income Tax / Deferred Tax Paid -		Operating Profit before working Capital Changes	(183,946)	(1,820,952)
Increase/Decrease in Payables & Provisions 68,240 26,605 Cash Generated From Operations (1,962,418) Income Tax / Deferred Tax Paid -		Adjustment for Capital Changes:		
Income Tax / Deferred Tax Paid			68,240	26,605
Income Tax / Deferred Tax Paid		Cash Generated From Operations	(283,777)	(1,962,418)
Net Cash From Investing Activities Increase/Decrease in Fixed Assets Increase/Decrease in Capital WIP Net Cash From Investing Activities Cash Flow From Investing Activities Increase/Decrease in Trade Payables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increas		Income Tax / Deferred Tax Paid	-	-
B Net Cash From Investing Activities Increase/Decrease in Fixed Assets Increase/Decrease in Capital WIP Net Cash From Investing Activities C Cash Flow From Financing Activities Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities 1,492,445 Net Increase (Decrease) in cash & cash equivalents (A+E (360,761) (1,962,289) Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		Extraordinary items	-	(1,710,556)
Increase/Decrease in Fixed Assets Increase/Decrease in Capital WIP Net Cash From Investing Activities Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Recei		Net cash from Operating Activities	(283,777)	(251,862)
Increase/Decrease in Fixed Assets Increase/Decrease in Capital WIP Net Cash From Investing Activities Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Increase/Decrease in Trade Receivables Increase/Decrease in Trade Recei	В	Net Cash From Investing Activities	-	-
Increase/Decrease in Capital WIP Net Cash From Investing Activities Cash Flow From Financing Activities Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Net Cash From Financing Activities Net Cash From Financing Activities Net Increase (Decrease) in cash & cash equivalents (A+F Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623	_		(168,071)	(168,071)
Cash Flow From Financing Activities Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrease in Trade Receivables Net Cash From Financing Activities Net Increase (Decrease) in cash & cash equivalents (A+E Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		Increase/Decrease in Capital WIP		-
Increase/Decrease in Trade Payables Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Increase/Decrea		Net Cash From Investing Activities	(1,569,429)	(168,071)
Increase/Decrease in Cash Loans and advances Increase/Decrease in Trade Receivables Net Cash From Financing Activities Net Increase (Decrease) in cash & cash equivalents (A+F Opening Balance of Cash & Cash Equivalents (296,000) (1,145,000) 497,202 1,492,445 (1,710,427) (1,962,289) 1,400,334 3,362,623	<u>c</u>	Cash Flow From Financing Activities		
Increase/Decrease in Trade Receivables 2,350,000 497,202 Net Cash From Financing Activities 1,492,445 (1,710,427) Net Increase (Decrease) in cash & cash equivalents (A+F (360,761) (1,962,289) Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		•	• • •	(1,062,629)
Net Cash From Financing Activities 1,492,445 (1,710,427) Net Increase (Decrease) in cash & cash equivalents (A+F Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623				
Net Increase (Decrease) in cash & cash equivalents (A+F (360,761) (1,962,289) Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		Increase/Decrease in Trade Receivables	2,350,000	497,202
Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		Net Cash From Financing Activities	1,492,445	(1,710,427)
Opening Balance of Cash & Cash Equivalents 1,400,334 3,362,623		Not Increase (Degrees) in each 2 cach against 14.5	(200.764)	(1.002.200)
		ivet increase (Decrease) in cash & cash equivalents (A+t	(360,761)	(1,962,289)
Closing Balance of Cash & Cash Equivalents 1,039,573 1,400,334			* * *	·
, , , , , , , , , , , , , , , , , , , ,		Closing Balance of Cash & Cash Equivalents	1,039,573	1,400,334

Place Mumbai

Date 14-Nov-19

For Rubra Medicaments Limited

Abna Kapoor
Director (Finance) & CFO

DIN: 02799429